SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (544)1/16/1998 4:37:00 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 1686
 
[ clarification regarding last post ]

The "violating open exchange" comment was not directed to V1. Since we've put the focus on CD40L in this thread, and since it is a project which is under-appreciated out in the real world, I was taking the op to comment to a reporter who lurks at SI (and sources info for articles here).

Sorry for any confusion.

Rick



To: scaram(o)uche who wrote (544)1/16/1998 9:41:00 PM
From: Harold Engstrom  Read Replies (2) | Respond to of 1686
 
Rick, do you mean that either Biogen or IMNX or some other company will commercialize applications for anti-CD40L or that you believe that Biogen will be the successful company pursuing its indications for CD40L? Thanks, Harold


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News